Top News · May 22, 2026 · 9:27

AI model overturns Erdős conjecture & Google rebuilds Search around AI - News (May 22, 2026)

AI breaks an Erdős conjecture, Google retools Search with Gemini, new cancer immune findings, obesity drug leaps, Taiwan tensions, and Ebola emergency.

AI model overturns Erdős conjecture & Google rebuilds Search around AI - News (May 22, 2026)
0:009:27

Our Sponsors

Today's Top News Topics

  1. AI model overturns Erdős conjecture

    — OpenAI says a new reasoning model produced an original proof that disproves a 1946 Paul Erdős discrete geometry conjecture, with outside mathematicians commenting. If confirmed, it strengthens the case for AI-assisted discovery and long-chain reasoning.
  2. Google rebuilds Search around AI

    — At Google I/O 2026, Google announced an AI-first Search experience powered by Gemini, shifting from blue links to summaries and chat-style follow-ups. The change could reshape web traffic, SEO, and how publishers and small businesses get discovered.
  3. Macrophages caught eating melanoma cells

    — Garvan Institute and UNSW filmed CD169-positive macrophages actively engulfing live melanoma cells in real time in mice, slowing tumor growth. The finding is notable because it appears to work independently of T cells and B cells, hinting at new immunotherapy angles.
  4. AI-designed miniproteins target key receptors

    — University of Washington researchers and Skape Bio used AI protein design to create tiny miniproteins that can switch GPCRs on or off in living cells. Because GPCRs are major drug targets, this could open new paths where conventional molecules struggle.
  5. Armored CAR-T shows promise in glioblastoma

    — UCLA’s cytokine-armored CAR-T approach against glioblastoma boosted anti-tumor immunity in immunocompetent mice, helping address antigen escape. Safety tweaks, including a VEGF-targeting element, aimed to reduce inflammation-linked toxicity.
  6. Retatrutide raises the bar in weight loss

    — Eli Lilly reported phase 3 data suggesting weekly retatrutide delivered larger average weight loss than current leading obesity drugs over 80 weeks. The results intensify competition while keeping tolerability and side effects in focus.
  7. Obesity body atlas flags nerve damage

    — German researchers introduced MouseMapper, an AI-driven whole-body atlas showing obesity-related changes at cellular resolution. A surprising signal was trigeminal nerve damage in mice, with similar molecular patterns found in human samples.
  8. Trump weighs Taiwan arms call

    — President Trump said he may speak directly with Taiwan’s President Lai about a possible arms sale, a break from decades of diplomatic practice. China condemned the idea, raising the risk of sharper US–China tensions over Taiwan.
  9. WHO declares Ebola global emergency

    — The WHO declared the DRC Ebola outbreak a Public Health Emergency of International Concern after spread into Uganda. The Bundibugyo strain complicates response because existing vaccines largely target other strains, making containment measures and supportive care crucial.

Sources & Top News References

Full Episode Transcript: AI model overturns Erdős conjecture & Google rebuilds Search around AI

An AI system may have just overturned a math assumption that’s held up since 1946—and this time, independent mathematicians are taking it seriously. Welcome to The Automated Daily, top news edition. The podcast created by generative AI. I’m TrendTeller, and today is May 22nd, 2026. Let’s get you caught up on what matters—and why.

AI model overturns Erdős conjecture

We’ll start in the world of AI and discovery. OpenAI says its newest general-purpose reasoning model has produced an original proof that disproves a well-known discrete geometry conjecture posed by Paul Erdős back in 1946. That’s a big claim in a field that doesn’t hand out credit easily—and it’s especially notable because OpenAI previously took heat after earlier “Erdős problem” claims turned out to overlap with already-known results. This time, the company pointed to supportive remarks from respected mathematicians, including some who had criticized the earlier episode. If the broader community validates the proof, it’s another sign that AI may be moving from summarizing knowledge to genuinely extending it—at least in some corners of mathematics.

Google rebuilds Search around AI

Staying with AI, Google says it’s about to remake how people use Search. At its 2026 I/O conference, the company described a “complete reimagining” of the search bar, shifting the experience toward AI-generated answers and a conversation-style interface powered by the Gemini 3.5 Flash model. Google is also leaning into richer inputs—like images and files—and even hints that Search can work more like an assistant that keeps an eye on topics and reports back. The immediate, real-world question is who wins and who loses when the answer shows up directly on the results page. Publishers, creators, and small businesses have been warning for months that AI summaries can mean fewer clicks, and fewer clicks can mean less revenue. This isn’t just a product tweak—it could change the economics of the open web.

Macrophages caught eating melanoma cells

Google is also pushing AI deeper into the smart home—though with a different strategy. The company says it wants Google Home to become a “full-stack AI offering,” combining its Home platform with Gemini-powered features that partners can build into their own devices and services. Read between the lines, and it looks like Google wants an ecosystem where internet providers, security companies, and device makers sell ongoing subscriptions on top of Google’s foundation. That could make smart homes more capable, but it also nudges the category further toward recurring fees—and potentially away from Google making as many of its own first-party devices.

AI-designed miniproteins target key receptors

Now to medical research, where a set of studies this week put the spotlight on immune cells and precision biology. In Australia, researchers at the Garvan Institute and UNSW Sydney captured striking footage: macrophages—immune cells typically known for cleaning up debris—actively attacking and engulfing live melanoma cells in real time. Using advanced microscopy in mice, they saw a particular macrophage subset, marked by a protein called CD169, patrolling tumor edges and essentially “eating” cancer cells. When those macrophages were depleted, tumors grew larger, suggesting these cells play a protective role. What makes this especially interesting is what it didn’t rely on. The anti-tumor activity appeared to occur independently of T cells and B cells—the immune players most current immunotherapies focus on. The team also found this macrophage population in healthy human skin and around the margins of human melanoma tumors, hinting it’s not just a mouse phenomenon. If future work holds up, it could point toward therapies aimed at boosting these macrophages—potentially helping in so-called “cold” tumors that don’t respond well to today’s checkpoint treatments.

Armored CAR-T shows promise in glioblastoma

Another immunotherapy update comes from UCLA, where scientists reported a preclinical CAR-T approach against glioblastoma—one of the toughest brain cancers to treat. Their engineered CAR-T cells target a glioblastoma-associated marker and are also designed to release immune-activating signals, aiming to pull more types of immune cells into the tumor. That matters because glioblastoma often dodges single-target therapies: some cancer cells simply don’t display the target, survive, and come roaring back. In mouse models with intact immune systems, the “cytokine-armored” CAR-T strategy improved tumor control and appeared to reduce one of the key barriers in solid tumors—escape through tumor diversity. Safety is the big caveat here, because immune-boosting signals can also trigger dangerous inflammation. The team tested additional design strategies to limit toxicity while keeping anti-tumor effects, and they say they’re working toward a first-in-human trial, pending further preclinical work and funding.

Retatrutide raises the bar in weight loss

Next, a different kind of precision medicine: AI-designed proteins that act more like custom-made switches. Researchers at the University of Washington’s Institute for Protein Design, working with startup Skape Bio, reported tiny “miniproteins” that can selectively turn certain G protein-coupled receptors—GPCRs—on or off. GPCRs are among the most important drug targets in medicine, involved in everything from hormones to mood to metabolism, but they’re notoriously tricky to control precisely because their binding regions can be deep and flexible. The team’s approach uses AI-driven design to build very small proteins that fit those hard-to-reach spots and stabilize either the active or inactive state of the receptor. They also built a high-throughput screening method that tests huge numbers of candidates directly in living human cells, which could speed up the hunt for effective designs. In a mouse study, one candidate performed comparably to an existing drug, with fewer side effects—a promising signal, even if it’s early days.

Obesity body atlas flags nerve damage

On the business-and-health intersection, Eli Lilly announced phase 3 results for its experimental weekly obesity injection, retatrutide, suggesting larger average weight loss than current leading drugs. In a trial of more than two thousand adults without diabetes, the highest dose group lost, on average, roughly 28 percent of body weight over 80 weeks—an eye-catching figure in a field that’s already moving fast. Side effects were common and mostly gastrointestinal, and they increased with dose—an important reminder that real-world success depends on what people can tolerate for the long haul. If the full data holds up under peer review and regulators sign off, these results could raise expectations for medical weight loss yet again—and intensify competition in a market that’s already reshaping healthcare, from cardiology to orthopedics to insurance coverage decisions.

Trump weighs Taiwan arms call

And obesity also leads us to a surprising science finding from Germany: an AI-driven “body atlas” that maps how obesity affects the entire body at cellular resolution, rather than looking at organs one at a time. The platform—called MouseMapper—combines whole-body imaging with AI analysis to build detailed 3D views. In mice fed a high-fat diet, researchers saw widespread inflammation and tissue changes across multiple organs. The standout, unexpected result was evidence of nervous-system damage: the trigeminal nerve showed fewer branches and endings, and the mice had reduced sensitivity in behavioral tests. Even more notable, when scientists checked human samples, they found similar molecular changes in the trigeminal ganglion in people with obesity. It’s not the final word, but it reframes obesity as a whole-body condition in a very literal way—and could help researchers connect symptoms that don’t always get linked to metabolism alone.

WHO declares Ebola global emergency

Now to geopolitics. President Donald Trump says he plans to speak with Taiwan’s President Lai Ching-te about a potential US arms sale—something that would break decades of diplomatic practice. Since the US switched formal recognition to Beijing in 1979, American support for Taiwan has been substantial but carefully managed, often avoiding direct leader-to-leader contact. China condemned the idea and warned against what it calls signals to separatism. Trump hasn’t decided whether to proceed with a reported multi-billion-dollar arms package, and Beijing is reportedly tying other US–China engagement to that decision. Coming right after Trump’s summit with China’s leader Xi Jinping—where Taiwan was described as a major flashpoint—this is the kind of move that can quickly raise temperatures across the Taiwan Strait, and across global markets watching for stability.

Finally, a major global health development: the World Health Organization has declared the Ebola outbreak in the Democratic Republic of the Congo a Public Health Emergency of International Concern after confirmed cases appeared in neighboring Uganda. The outbreak is being driven by the Bundibugyo strain, and that detail matters because existing Ebola vaccines were largely built around a different strain. Health officials emphasize that Ebola spreads through direct contact with infected bodily fluids—not through the air—and people aren’t contagious before symptoms begin. But cross-border movement can outpace detection, especially in regions with frequent travel and limited resources. With no approved Bundibugyo-specific vaccine or targeted treatment, the response depends on fast diagnosis, isolation, contact tracing, safe burials, and supportive hospital care. The emergency declaration is meant to unlock funding and coordination quickly—and it’s also a reminder that preparedness needs to cover more than one viral “version.”

That’s the rundown for May 22nd, 2026. If one theme ties today together, it’s this: whether it’s AI reshaping search, immune cells doing unexpected work, or outbreaks crossing borders, small shifts can have outsized consequences. Thanks for listening to The Automated Daily - Top News Edition. I’m TrendTeller—check back tomorrow for the next briefing.

More from Top News